```html

Kenya Fever (Malaria) – Comprehensive Medical Guide

Overview

“Kenya fever” is a colloquial term used in Kenya and parts of East Africa for malaria, an infectious disease caused by parasites of the genus Plasmodium that are transmitted to humans through the bite of an infected female Anopheles mosquito.

• Who it affects: Everyone can be infected, but children under five, pregnant women, people with weakened immune systems, and travelers who lack immunity are at highest risk.
• Prevalence: According to the World Health Organization (WHO), Kenya accounted for ~1.2 million malaria cases in 2023, representing roughly 5 % of the global burden. The disease is endemic in low‑lying, humid regions such as the coastal belt, western Kenya, and the Lake Victoria basin.<sup>[1] WHO World Malaria Report 2023</sup>

Malaria remains a leading cause of outpatient visits and hospital admissions in Kenya. Prompt recognition and treatment are crucial because severe malaria can be fatal within 24 hours.

Symptoms

Symptoms typically appear 7‑30 days after the infective mosquito bite, depending on the Plasmodium species. The most common species in Kenya are P. falciparum (≈ 85 % of cases) and P. vivax (≈ 15 %).

Early (Uncomplicated) Malaria

• Fever or chills – sudden high temperature often with shaking chills.
• Headache – throbbing, may worsen with fever.
• Fatigue & weakness – generalized tiredness, difficulty performing daily tasks.
• Muscle and joint pains – achy feeling similar to flu.
• Nausea, vomiting, or abdominal pain.
• Diarrhea – occasional, more common in children.
• Chills followed by sweating – classic “paroxysm” pattern.

Severe (Complicated) Malaria

Occurs most often with P. falciparum. Warning signs include:

• Altered mental status or seizures (cerebral malaria).
• Difficulty breathing or rapid breathing.
• Severe anemia (hemoglobin < 5 g/dL).
• Kidney failure (reduced urine output, dark urine).
• Jaundice (yellowing of skin/eyes).
• Low blood pressure or shock.
• Bleeding or easy bruising (coagulopathy).

Causes and Risk Factors

Cause

Malaria is caused by microscopic parasites. The life cycle involves:

1. Infected Anopheles mosquito takes a blood meal.
2. Parasites (sporozoites) enter the bloodstream and travel to the liver.
3. They multiply in liver cells, then re‑enter the blood as merozoites, infecting red blood cells.
4. Replication inside red blood cells leads to cell rupture, releasing more parasites and causing fever spikes.

Risk Factors

• Geography: Living in or traveling to endemic zones, especially rural areas with poor housing.
• Season: Rainy season (April‑June, October‑December) increases mosquito breeding.
• Age & pregnancy: Children <5 years and pregnant women have reduced immunity.
• Immunosuppression: HIV, malnutrition, or chronic diseases.
• Lack of preventive measures: No insecticide‑treated nets (ITNs), no indoor residual spraying (IRS), or failure to take chemoprophylaxis when traveling.
• Genetic factors: Certain hemoglobinopathies (e.g., sickle‑cell trait) confer partial protection; conversely, G6PD deficiency can affect treatment choices.

Diagnosis

Prompt diagnosis reduces morbidity and mortality. The gold‑standard is microscopic examination, but rapid tests are widely used in field settings.

1. Microscopic Blood Smear

• Thick smear: Concentrates parasites, used for detection.
• Thin smear: Identifies Plasmodium species and estimates parasite density (parasites/µL).
• Requires trained laboratory personnel; results within 30‑60 minutes.

2. Rapid Diagnostic Tests (RDTs)

• Detect specific antigens (HRP2 for P. falciparum, pLDH for non‑falciparum).
• Results in 15‑20 minutes, useful where microscopy isn’t available.
• False‑negatives can occur with HRP2‑deleting parasites; confirm with microscopy if clinical suspicion remains high.

3. Molecular Tests (PCR)

• Highly sensitive; used for research, surveillance, or to resolve ambiguous cases.
• Not routinely available in most Kenyan health facilities due to cost.

4. Additional Labs (for severe disease)

• Complete blood count (CBC) – assesses anemia, platelet count.
• Liver function tests, renal panel – detect organ involvement.
• Blood glucose – hypoglycemia is a frequent complication in severe malaria.

Treatment Options

Treatment follows national Kenyan guidelines (Kenya Ministry of Health, 2022) and WHO recommendations. Prompt therapy within 24 hours of symptom onset is essential.

Uncomplicated Malaria

• Artemisinin‑based Combination Therapy (ACT) – first‑line for P. falciparum.
  • Examples: Artemether‑lumefantrine (Coartem), Artesunate‑amodiaquine, Dihydroartemisinin‑piperaquine.
  • Typical course: 3‑day regimen, taken with food to improve absorption.
• Chloroquine – still effective for P. vivax in areas without resistance (rare in Kenya).
• Primaquine (single dose 0.25 mg/kg) – added after ACT to eradicate liver hypnozoites of P. vivax and prevent relapse. Must check G6PD status first.

Severe (Complicated) Malaria

• Parenteral Artesunate – preferred IV/IM therapy for 24 hours or until patient can tolerate oral meds.
• Alternative parenteral agents (if artesunate unavailable): quinine or quinidine (requires cardiac monitoring).<sup>[2] CDC Malaria Treatment Guidelines 2024</sup>
• After stabilisation, transition to a full ACT course.
• Supportive care:
  • IV fluids (cautiously, to avoid pulmonary edema).
  • Blood transfusion for severe anemia.
  • Anticonvulsants (e.g., diazepam) for seizures.
  • Renal replacement therapy if acute kidney injury develops.

Lifestyle & Adjunct Measures

• Maintain adequate hydration.
• Fever control with acetaminophen (avoid NSAIDs if renal impairment is present).
• Nutrition: iron‑rich diet after recovery from anemia, but avoid iron supplements during acute infection unless indicated.

Living with Kenya Fever (Malaria)

Even after cure, people who live in endemic areas may experience repeated infections. Long‑term management focuses on health maintenance and vigilance.

Daily Management Tips

1. Use Insecticide‑Treated Nets (ITNs) every night, even during dry months.
2. Inspect and repair net holes weekly.
3. Sleep under a net before sunset – mosquitoes bite from dusk to dawn.
4. Wear protective clothing (long sleeves, long trousers) in evenings.
5. Apply EPA‑registered repellents containing DEET (≥30 %), picaridin, or IR3535 to exposed skin.
6. Keep doors and windows screened or use indoor residual spraying (IRS) where available.
7. Promptly treat any fever – use a rapid test or seek medical care rather than self‑diagnosing.
8. Maintain routine health checks – CBC every 6‑12 months for people with a history of severe malaria.
9. Adhere to follow‑up visits after treatment to ensure parasite clearance (repeat smear/RDT after 24‑48 h).

Psychosocial Considerations

• Stigma: In some communities, repeated malaria can be misinterpreted as “weakness.” Education campaigns help mitigate this.
• Work/school absenteeism: Plan for possible episodes during peak transmission months.
• Travel: Carry a travel health kit that includes an RDT (if allowed), ACT tablets, and a written action plan.

Prevention

Prevention is a combination of vector control, personal protection, and, when appropriate, chemoprophylaxis.

Vector Control

• Insecticide‑treated bed nets (ITNs): Distribute free nets through national campaigns; replace every 3 years.
• Indoor Residual Spraying (IRS): Annual spraying with long‑acting insecticides (e.g., pirimiphos‑methyl).
• Environmental management: Drain stagnant water, clear vegetation near homes, and cover water storage containers.

Personal Protective Measures

• DEET‑based repellents applied to skin and clothing.
• Protective clothing, especially during outdoor evening activities.
• Use of fans or air‑conditioning to reduce indoor mosquito presence.

Chemoprophylaxis (for travelers)

• Atovaquone‑proguanil (Malarone) – daily, started 1‑2 days before travel and continued 7 days after leaving.
• Doxycycline – daily, started 1‑2 days before travel and continued 4 weeks after return.
• Mefloquine – weekly, started at least 2 weeks before travel; not suitable for people with psychiatric history.
• Consult a travel clinic for personalized advice; resistance patterns may influence drug choice.

Vaccination

The RTS,S/AS01 (Mosquirix) vaccine has been piloted in Kenya since 2019 for children aged 5‑17 months, showing a ~30 % reduction in clinical malaria episodes. It is not yet part of the routine national schedule but may become more widely available in the future.<sup>[3] WHO Malaria Vaccine Implementation Programme 2024</sup>

Complications

If not treated promptly, malaria can progress to life‑threatening conditions.

• Cerebral malaria: Seizures, coma, long‑term neurological deficits.
• Severe anemia: May require transfusion; can impair growth in children.
• Acute respiratory distress syndrome (ARDS): Rapid breathing and low oxygen levels.
• Acute kidney injury: Oliguria or anuria, may need dialysis.
• Hypoglycemia: Particularly in pregnant women and children.
• Hemoglobinuria (blackwater fever): Massive hemolysis leading to dark urine and renal failure.
• Placental malaria: Increases risk of low birth weight, preterm delivery, and maternal mortality.

When to Seek Emergency Care

References

1. World Health Organization. World Malaria Report 2023. Geneva: WHO; 2023. https://www.who.int/publications/i/item/9789240061029
2. Centers for Disease Control and Prevention. CDC Yellow Book 2024: Malaria Treatment Guidelines. Atlanta, GA: CDC; 2024. https://www.cdc.gov/malaria/travelers/drugs.html
3. World Health Organization. WHO Malaria Vaccine Implementation Programme (MVIP) – Kenya. 2024. https://www.who.int/teams/global-malaria-programme/vaccines
4. Mayo Clinic. Malaria - Symptoms and Causes. Updated June 2024. https://www.mayoclinic.org/diseases-conditions/malaria/symptoms-causes/syc-20351184
5. Cleveland Clinic. Malaria: Diagnosis and Treatment. 2023. https://my.clevelandclinic.org/health/diseases/16832-malaria

```